Chronic lymphocytic leukaemia vaccine (MaxCyte)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameChronic lymphocytic leukaemia vaccine (MaxCyte)

Drug Alias Name慢性淋巴细胞白血病疫苗 - MaxCyteGene modified autologous B-CLL cell therapy

ClassificationVaccines > Application > Therapeutic vaccine

Mechanisms of ActionN/A

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMaxcyte Inc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

ATC CodeN/A